Keyword: Bristol-Myers Squibb
Fierce 15 winner Kronos Bio has poached Jorge DiMartino, M.D., Ph.D., as its chief medical officer and EVP of clinical development.
Combining a checkpoint inhibitor with an anti-TFG-beta drug was effective in mouse models of metastatic prostate cancer, MD Anderson researchers said.
The phase 1/2 results show the efficacy seen at 12 months has persisted, providing early evidence of durable responses.
The data look competitive against Gilead’s Yescarta and Novartis’ Kymriah, leading analysts to predict Celgene will win FDA approval next year.
The series B funding will ramp up PathAI's R&D into new digital tools and medical devices for the diagnosis of diseases like cancer.
Amid the merger of Celgene and his former company Bristol-Myers Squibb, there was no room at the inn for oncologist Thomas Lynch, M.D., as CSO.
Most top R&D executives from across biopharma are earning around $7 million a year.
7. Thomas Lynch, Bristol-Myers Squibb
The top research and development executives from across biopharma are certainly not looking down the back of the sofa for change; most are earning around $7 million a year. But then the job is tough, and arguably just as important as the top CEO job, given how much companies rely on the strength of their R&D.
Rapt Therapeutics filed to raise up to $75 million in its IPO after postponing an earlier attempt to raise $86 million in August.